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Abbreviations 34 
FA, Fatty acid; PL, Phospholipid; LPL, lysophospholipids; CoA, Coenzyme A; DAG, 35 
Diacylglyceride; TG, Triacylglyceride; LD, Lipid droplets; ATP, Adenosine triphosphate; 36 
DNL, De novo lipogenesis; AKT, Protein kinase B; LPA, lysophosphatidic acid; PA, 37 
phosphatidic acid; ACLY, ATP-citrate lyase; ACC, Acetyl-CoA carboxylase; FAS, Fatty 38 
acid synthase; MAGL, Monoacylglycerol lipase; OAA, oxaloacetate; PI3K, Phosphoinositide 39 
3-kinase; SREBP-1, sterol regulatory element-binding protein 1; ACSS2, acyl-CoA 40 
synthetase short-chain family member 2; AMP, Adenosine monophosphate; AMPK, AMP-41 
activated protein kinase; hACLY, Human ACLY; LDL-C, Low-density lipoprotein 42 
cholesterol; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; RTK, receptor tyrosine kinase; 43 
STAT3, signal transducer and activator of transcription 3; MAPK, Mitogen-activated protein 44 
kinase; mTOR, mammalian target of rapamycin; SAR, Structure–activity relationship; BC, 45 
biotin carboxylase; CT, carboxyltransferase; BCCP, biotin carboxyl carrier protein; CPT1, 46 
carnitine palmitoyltransferase 1; ChREBP, Carbohydrate-responsive element-binding protein; 47 
CAs, -carbonic anhydrases; PPAR, peroxisome proliferator-activated receptor; HER2, 48 
human epidermal growth factor receptor-2; H-bond, hydrogen bond; rACC, rat ACC; 49 
GPAT1, glycerol-3-phosphate acyltransferase; VLDL, very low-density lipoprotein; NSCLC, 50 
non-small-cell lung cancer; hFAS, Human FAS; TE, Thioesterase domain; ACP, Acyl-carrier 51 
protein domain; KR, -ketoacyl reductase domain; ER, Enoyl reductase domain; DH, -52 
hydroxyacyl dehydratase; MAT, Malonyl/acetyl transferase; KS, -ketoacyl synthase; YKR, 53 
pseudoketoreductase; YME, pseudomethyltransferase; NADPH, Nicotinamide adenine 54 
dinucleotide phosphate; EGF, Epidermal growth factor; SREBP-1c, Sterol regulatory 55 
element-binding protein 1; USP2a, Ubiquitin-specific cysteine protease 2a; FFAs, free fatty 56 
acids; MAGs, monoacylglycerols; LPC, lysophosphatidylcholine; LPE, 57 
lysophosphatidylethanolamine; PA, phosphatidic acid; PGE2, Prostaglandin E2; MAGE, 58 
Monoalkylglycerol; 2-AG, 2-arachidonoylglycerol; CB1, Cannabinoid receptor type 1; CB2, 59 
Cannabinoid receptor type 2; FAAH, fatty acid amide hydrolase; ABHD6, α/β hydrolase 60 
domain 6; ABHD12, α/β hydrolase domain 12; hMAGL, human MAGL; HCC, 61 
hepatocellular carcinoma. 62 
63 
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 64 
Abstract 65 
Cancer cells rely on several metabolic pathways such as lipid metabolism to fulfill the 66 
increase in energy demand, cell division and growth and successful adaptation to challenging 67 
environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell 68 
lines. Thus, relevant efforts are being made by the scientific community to inhibit the 69 
enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the 70 
rapidly expanding body of inhibitors targeting lipid metabolism, their side effects, and 71 
current status in clinical trials as potential therapeutic approaches against cancer. We focus 72 
on their molecular, biochemical, and structural properties, selectivity and effectiveness and 73 
discuss their potential role as antitumor drugs.  74 
Keywords 75 
Cancer drugs, lipid metabolism, lipogenic enzyme inhibitors 76 
 77 
Introduction 78 
Many types of cancers are detected each year around the globe. According to the World 79 
Health Organization cancer is the second cause of death, bringing a disturbing number of 9.6 80 
million deaths in 2018  (1). Cancer is a disorder of cell growth and proliferation that requires 81 
high amounts of energy and cellular building blocks including nucleic acids, proteins, and 82 
lipids  (2). Lipids comprise a wide group of biomolecules make-up of fatty acids (FAs) of 83 
different chain length, number and location of double bonds, and backbone structure  (3). 84 
Lipid metabolism is of special interest in cancer therapy because lipids are involved in 85 
multiple biochemical processes during cancer initiation and development  (2). Lipids 86 
participate in the growth, energy and redox homeostasis of cancer cells. Moreover, they have 87 
structural roles as passive components of cell membranes, like cholesterol and sphingolipids 88 
that are important components of membrane rafts  (2, 4). Furthermore, they initiate some 89 
signal transduction cascade processes and also can be broken down into bioactive lipid 90 
mediators that regulate cancer cell growth, migration, and metastasis formation  (4–6). 91 
The high rate of cancer cell proliferation requires an accelerated synthesis of lipids for the 92 
generation of biological membranes  (2, 5, 6). The metabolic cycles of cancer cells are 93 
altered, due to a series of oncogenic events and the tumor microenvironment, to satisfy the 94 
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energy and lipids requirements  (6, 7). The most well-known perturbation in the metabolic 95 
cycle of cancer cells is the Warburg effect, which implies an increase in glucose uptake and 96 
the use of aerobic glycolysis (Figure legends 97 
Figure 1)  (8). Other important perturbations enhanced as part of cancer-associated 98 
metabolic reprogramming includes the biosynthesis of proteins, nucleic acids, and lipids  (3, 99 
6). Specifically, lipid biosynthesis is induced as part of the anabolic metabolism of cancer 100 
cells and it is the process to convert nutrient-derived carbons (that normally are an energy 101 
source) into FAs (Figure legends 102 
Figure 1) and cholesterol  (3, 4, 6). 103 
 104 
Lipids’ role in cancer 105 
The main building blocks of cell membranes are phospholipids (PLs), sterols, 106 
sphingolipids and also lysophospholipids (LPL) (Figure legends 107 
Figure 1). All of them are derived from acetyl-CoA and many contain FAs  (3). The FAs 108 
structure consists of a terminal carboxyl group and a hydrocarbon chain (usually with an even 109 
number of carbons) that can be saturated or unsaturated  (3). FAs can be used to generate 110 
many different types of lipids including diacylglycerides (DAGs) and triacylglycerides 111 
(TGs); this last one is mainly used for energy storage in the form of lipid droplets (LDs)  (2, 112 
4, 6). Moreover, DAGs and TAGs are synthesized via glycerol phosphate pathway, which 113 
uses the glycolytic intermediate glycerol-3-phosphate to form the glycerol backbone of these 114 
lipids; the intermediates in this process can be converted into different phosphoglycerides 115 
that are the major structural components of biological membranes  (3, 6). 116 
Cancer cells can obtain FAs either from exogenous sources or from de novo lipogenesis 117 
(DNL)  (2, 3). In the presence of oxygen and abundant extracellular nutrients, most cancer 118 
cells synthesize FAs de novo (Figure legends 119 
Figure 1); but under conditions of metabolic stress, they collect extracellular lipids as an 120 
adaptation to survive  (9). This adaptation implies a reduction of the carbon supply and power 121 
for the FAs synthetic pathway  (7). Moreover, FAs can be used as an energy source when 122 
mitochondrial oxidation (-oxidation) occurs (Figure legends 123 
Figure 1); they produce more than the double of ATP per mol when compared to the 124 
glucose or aminoacids oxidation  (2–4, 6, 7). Consequently, some cancer cells prefer to use 125 
FAs as an energy source even under nutrient-replete conditions  (7). 126 
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Another important biosynthetic process within lipid metabolism is the mevalonate 127 
pathway, which facilitates the synthesis of cholesterol  (2, 4, 6). Cholesterol is one of the 128 
main components of biological membranes, as it modulates the fluidity of the lipid bilayer, 129 
and also forms detergent-resistant microdomains called lipid rafts, that coordinate the 130 
activation of some signal transduction pathways  (2, 4, 6). In cancer cells, many signaling 131 
proteins as protein kinase B (Akt), and receptors regulating prooncogenic and apoptotic 132 
pathways reside in lipids rafts  (2). Moreover, the activation of oncogenic signaling pathways 133 
only depends on the lipid rafts integrity, therefore, by disrupting them, the activation of the 134 
anchored-lipid raft Akt protein is inhibited and the tumor cell proliferation is reduced  (10). 135 
Some of the already mentioned characteristics of cancer cells, improve their proliferation 136 
and resistance to chemotherapy. TGs and cholesteryl esters are stored in LDs, which are 137 
highly ordered intracellular structures formed in the endoplasmic reticulum  (4). LDs are 138 
typically found in some aggressive cancers as well as high levels of saturated FAs in some 139 
aggressive breast cancers  (11). Cancer cells have higher amounts of LDs compared with 140 
normal tissue, which enhances their resistance to chemotherapy  (12). Moreover, the high 141 
levels of saturated FAs increase the levels of saturated PLs in cancer cells, reducing the 142 
membrane fluidity and protecting cancer cells from oxidative damage  (6). 143 
Lipids are also important signaling molecules. For example, phosphoinositides are a 144 
family of second messengers that transmit signals from activated growth factor receptors to 145 
the cellular machinery  (6, 13). Besides, the phosphoinositides act as specific binding sites for 146 
the coupling of effector proteins into specific membrane sites  (6). Other lipids that act as 147 
second messengers are lysophosphatidic acid (LPA), phosphatidic acid (PA) and DAG  (6). 148 
Moreover, sphingolipids are other important signaling molecules (Figure legends 149 
Figure 1); the simplest of them is ceramide  (6). In cancer cells, ceramide mediates 150 
growth inhibitory signals and is involved in the initiation of the apoptotic process and growth 151 
arrest  (6). Furthermore, the enzymes involved in the sphingolipid metabolism pathway are 152 
normally deregulated in cancer cells, producing low ceramide levels and the consequently 153 
increased resistance to chemotherapy  (14).  154 
Besides the already mentioned lipids employment in cancer cells, lipids have an important 155 
role in post-translational modification of proteins  (6). Palmitate and myristate are saturated 156 
acyl chains that are normally (covalently) coupled to proteins and improve the protein 157 
interaction with membrane rafts  (15). Lipid metabolism is also involved in the autophagic 158 
process, which is a mechanism of self-degradation required for the removal of defective 159 
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proteins and organelles. Moreover, the autophagic process is favored under conditions of 160 
nutrient scarcity and enhances the survival of cancer cells by contributing to the maintenance 161 
of energy supply during tumorigenesis  (16). 162 
Apart from the importance of lipids in cancer cells proliferation and survival, they are also 163 
implicated in other more complex processes as cell migration, invasion, tumor angiogenesis 164 
and metastasis formation  (6). Finally, the overexpression of lipogenic enzymes (Figure legends 165 
Figure 1), such as ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid 166 
synthase (FAS), and monoacylglycerol lipase (MAGL), represent a nearly-universal 167 
phenotypic alteration in most tumors and cancer cells (Figure legends 168 
Figure 1)  (3, 7). In this review, we will focus on the description of the lipogenic enzymes 169 
mentioned above, and some inhibitors of each of them as potential therapeutic targets against 170 
cancer. 171 
 172 
Lipogenic enzymes’ inhibitors 173 
ACLY 174 
Function and description. The ACLY is the key enzyme of the conversion of citrate 175 
derived from glycolytic metabolism into acetyl-CoA (Figure legends 176 
Figure 1); which is the starting material of two highly important processes in DNL, the 177 
FA synthesis and mevalonate pathway  (17). The human ACLY is a homotetramer of about 178 
0.5 MDa, where each polypeptide chain is formed by 1,101 amino-acid residues. It consists 179 
of an N-terminal citryl-CoA synthetase module and a C-terminal citryl-CoA lyase domain  180 
(18, 19). It has five functional domains divided into two subunits. The α-subunit has two 181 
domains, the domain 1 binds CoA, and the domain 2 contains the phosphorylated histidine 182 
residue. In the β-subunit, the domain 3 and 4 adopt an ATP-grasp fold and bind ATP, and the 183 
domain 5 stimulates domain 2 to form a helix dipoles called "power helices" that stabilize the 184 
phosphorylated histidine residue at the N-terminal domain and arranges the binding site of 185 
citrate  (20, 21). 186 
In more detail, the ACLY is a cytosolic enzyme that catalyzes the conversion of citrate 187 
(transported from the mitochondria) and CoA into acetyl-CoA and oxaloacetate (OAA) in the 188 
presence of magnesium complex Mg-ATP  (17). Initially, the catalysis starts by 189 
autophosphorylation of a histidine residue, resulting in a citryl-phosphate within the active 190 
site. Subsequently, a covalent citryl-enzyme complex is produced and is attacked by the CoA 191 
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to form the citryl-CoA. Finally, the enzyme catalyzes the cleavage of citryl-CoA to acetyl-192 
CoA and OAA  (22). 193 
The ACLY is overexpressed in many different cancer cell lines, stimulated by insulin, 194 
growth factors, and high levels of glucose  (23). Moreover, the stimulation mechanism occurs 195 
through the phosphoinositide 3-kinase (PI3K)/Akt pathways. The Akt pathway upregulates 196 
the ACLY by the activation of the sterol regulatory element-binding protein 1 (SREBP-1), 197 
which is a transcription factor for genes involved in FA and cholesterol synthesis  (22, 24). 198 
On the other hand, the PI3K/Akt pathways stimulates the ACLY through its phosphorylation 199 
(contributing to the protein stabilization) rather than transcriptional upregulation  (17, 25). 200 
Also, ACLY is regulated by other pathways depending on the cell line  (22, 24). Furthermore, 201 
when ACLY is deregulated, the expression of the acyl-CoA synthetase short-chain family 202 
member 2 (ACSS2) increases, catalyzing the conversion of exogenous acetate to acetyl-CoA 203 
using ATP  (18, 24). 204 
Inhibitors and cytotoxic effects. The inhibition of ACLY produces cytotoxic effects by 205 
disrupting FA synthesis, similar to the FAS and ACC inhibition (mentioned in next sections)  206 
(17, 26). Moreover, ACLY inhibition affects the mevalonate pathway, disrupting the 207 
cholesterol and isoprenoids synthesis, and thus, enhancing its cytotoxic effect  (17). 208 
Furthermore, the ACLY inhibition produces stronger cytotoxic effects in cells with elevated 209 
glucose metabolism than in others with a low aerobic glycolysis  (27). It evidences that some 210 
cancer cells are independent of ACLY to produce acetyl-CoA, like the ones that use ACSS2  211 
(23). Other important effect of the ACLY inhibition, is the increase of intracellular amounts 212 
of reactive oxygen species; enhancing the phosphorylation of an important regulator of lipid 213 
metabolism, the AMP-activated protein kinase (AMPK)  (21). 214 
Several studies have shown that many ACLY inhibitors produce cytotoxic effects against 215 
some cancer cell lines, and can be enhanced in combination with other agents that block 216 
oncogenic receptor signaling  (23). The human ACLY has been widely studied and many 217 
potent inhibitors have been developed (Figure 2). First, the (–)-Hydroxycitric acid (1, Figure 218 
2), it is a naturally occurring compound extracted for the first time from fruits of Garcinia  219 
(28). It is a competitive inhibitor of ACLY with a Ki value of 300 μM. Some preclinical 220 
studies for cancer therapy were performed with this compound, in co-treatment with lipoic 221 
acid (a pyruvate dehydrogenase kinase inhibitor) and cisplatin (a classical chemotherapeutic 222 
that binds DNA). In vivo studies, showed that the combination of those three drugs, by 223 
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attacking the altered metabolism and DNA of cancer cells, brings some improvement when 224 
compared to cisplatin treatment (monotherapy)  (28). 225 
Other natural product, the 2-chloro-1,3,8-trihydroxy-6-methylanthrone (2, Figure 2), was 226 
found to be a strong inhibitor of hACLY with an IC50 of 283 nM  (29). Compound 2 was 227 
extracted from active microbial metabolite derived from a soil fungus (Penicillium sp). 228 
Despite promising results, no cytotoxic study was carried out using this compound against 229 
cancer cells.  230 
Other compound of natural origin is Cucurbitacin B (3, Figure 2), found in cucumber 231 
among other members of the Cucurbitaceae family with tetracyclic triterpenoid structure  232 
(30). In vitro studies showed that Cucurbitacin B is cytotoxic against different cancer cell 233 
lines, including breast SK-BR-3 (IC50 = 4.6 µg/mL), MCF7 (IC50 = 88.7 µg/mL  (31), 48.6 234 
µg/mL), MDA-MB-231 (IC50 = 38.9 µg/mL), lung NCI-H460 (about 87% inhibition after 235 
48h with 0.1 µM of drug), central system SF-268 ( about 92% inhibition after 48h with 0.05 236 
µM of drug)  (30), colon HCT-116 (about 80% inhibition after 48h with 0.4 µM of drug)  237 
(32), pancreas PC-3 and LNCaP (IC50 ~ 0.3 µM)  (33), and hepatocellular BEL-7402 (IC50 = 238 
0.32 µM)  (34). The mechanism of action of Cucurbitacin B, was linked to several targets and 239 
it is not fully elucidated. However, Xiao et al. demonstrated in vitro and in vivo dose 240 
depending ACLY inhibition by this compound  (33). Additionally, several in vivo studies in 241 
xenograft rat models showed tumor reduction after treatment with Cucurbitacin B  (18, 33). 242 
Recently, the pharmacokinetic of Cucurbitacin B was studied demonstrating limited 10% low 243 
oral bioavailability, however, large volume of distribution into internal organs  (35). 244 
Synthetic inhibitors of ACLY has been extensively reviewed  (18), however, it is worth 245 
mentioning the most potent and promising compounds (Figure 2). ETC-1002 or Bempedoic 246 
acid (4, Figure 2) was developed by Esperion Therapeutics Inc, and is currently in the phase III 247 
of clinical trials to reduce low-density lipoprotein cholesterol (LDL-C), and prevent 248 
cardiovascular related diseases  (36). In the liver, it is converted to its active form (ETC-249 
1002-CoA) by the acyl-CoA synthase. The ETC-1002-CoA inhibits the ACLY completely, 250 
reducing the OAA and acetyl-CoA levels to finally disrupt DNL. Moreover, it increases the 251 
AMPK activity, inhibiting the phosphorylation of ACC and HMG-CoA reductase, and thus, 252 
reducing the glucose and lipid biosynthesis  (18). 253 
In 2007 a series of 2-hydroxy-N-arylbenzenesulfonamides compounds were reported as 254 
strong inhibitors of ACLY  (37). The most potent one, was the compound 5 (Figure 2) with an 255 
IC50 of 130 nM. Although it showed high enzymatic inhibition activity, compound 5 has 256 
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weak cytotoxicity (> 50 µM) against human liver carcinoma HepG2 cell line. The biological 257 
activity study of this compound was focus once again in decreasing cholesterol and TGs, and 258 
not for FAs  (37). 259 
Very recently, a novel series of compounds were synthesized with similar structure to 260 
compound 5. Specifically, Wey et al. developed the compound NDI-091143 (6, Figure 2), 261 
maintaining the benzenesulfonamide connected to biphenyl moiety but substituting one of the 262 
chlorides with a methoxycarbonyl group on the phenolic part, and incorporating two fluorine 263 
atoms on the biphenyl moiety  (38). Those changes improve greatly the inhibitory effect of 264 
NDI-091143, and it became the strongest inhibitor of ACLY known so far with a Ki of 7.0 265 
nM and an IC50 between 2.1- 4.8 nM. Interestingly, the authors were able to obtain ACLY-266 
NDI-091143 co-crystal structure using a cryo-electron technique and observed that NDI-267 
091143 occupies the polar citrate domain of ACLY; which is surprising because of the lack 268 
of carboxylic moieties in the drug. The conformational changes of the amino acid residues, 269 
allowed the binding of the drug, leading the authors to conclude that NDI-091143 is the first 270 
allosteric inhibitor of ACLY  (38, 39). These recent discoveries most likely will permit the 271 
finding of novel ACLY inhibitors with similar or even better inhibition activity which is very 272 
exciting in terms of anticancer drug discovery targeting lipogenic enzymes. 273 
A natural compound found in the bark of pine trees, is a diterpene amine called Leelamine 274 
(7, Figure 2), it demonstrated cytotoxic activity against many cell lines including melanoma, 275 
prostate and breast cancer  (40). Leelamine targets key oncogenic pathways including the 276 
receptor tyrosine kinase (RTK)-Akt/signal transducer and activator of transcription 3 277 
(STAT3)/ mitogen-activated protein kinase (MAPK), and the Akt/mammalian target of 278 
rapamycin (mTOR) pathways  (40). Recently, it has been found that treating prostate cancer 279 
in vitro and in vivo with Leelamine, the FA synthesis is disrupted by the downregulation of 280 
protein and/or mRNA expression of ACLY (41).  281 
The compound 8 (Figure 2), also known as DCV (10,11-dehydrocurvularin), is a macrolide 282 
and fungus-derived natural-product recently connected with ACLY target; showing cytotoxic 283 
activity against some cancer cell lines  (42). This recent work, performed a proteome-wide 284 
analysis using classical chemo-proteomic profiling in living cell models treated with DCV  285 
(42). Deng et al. have found that DCV is a strong irreversible ACLY inhibitor with an IC50 of 286 
0.93 µM. Moreover, some SAR studies were performed with some few derivatives of DCV. 287 
The reduction of the conjugated double bond in the lactone moiety causes the loss of 288 
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cytotoxic activity; which suggests that the macrolide binds with its target by Michael addition 289 
mechanism probably with protein cysteine-thiol nucleophile. 290 
The presented inhibitors of ACLY enzyme are promising in terms of cancer treatment. 291 
However, many studies with ACLY targeting drugs are focusing exclusively on treatment of 292 
cardiovascular diseases and for that reason less information regarding the cytotoxicity and 293 
effectiveness for cancer treatment is available.  294 
ACC 295 
Function and description. The ACC is the rate-limiting enzyme in FA synthesis as it 296 
catalyzes the formation of malonyl-CoA (Figure legends 297 
Figure 1), which is one of the necessary substrates for the next step (catalyzed by FAS)  298 
(43). In more detail, the ACC is a biotin-dependent multidomain enzyme located in the 299 
endoplasmic reticulum, it contains a biotin carboxylase (BC) and a carboxyltransferase (CT) 300 
active sites. The full crystal structure of the human ACC has not been elucidated yet but it is 301 
believed that it is similar to the ACC from yeast, in which the BC and CT domains are the 302 
active sites; and the biotin is covalently linked to the biotin carboxyl carrier protein (BCCP) 303 
domain, which is translocated during catalysis  (44). In the first step of the reaction, the BC 304 
catalyzes the ATP-dependent carboxylation of biotin with bicarbonate serving as the CO2 305 
source and in the second step, the CT promotes the carboxyl transfer from biotin to acetyl-306 
CoA and malonyl-CoA is formed  (43, 45). 307 
There are two known isoforms of ACC in mammals, the ACC1 and the ACC2  (43). The 308 
ACC1 is mainly found in the cytosol of lipogenic tissues such as liver, adipose tissue, and 309 
lactating mammary gland and catalyzes the malonyl-CoA formation in the FA synthesis  (43, 310 
46). It has been reported as up-regulated in some types of human cancer including breast, 311 
prostate, lung, ovary, and colon  (47). On the other hand, the ACC2 is commonly found in the 312 
outer membrane of more oxidative tissues such as skeletal muscle and heart and also in the 313 
metabolically active liver. In these tissues, the ACC2 functions as a regulator of the FA -314 
oxidation (Figure legends 315 
Figure 1) by the inhibition of carnitine palmitoyltransferase 1 (CPT1) via malonyl-CoA  316 
(48). The human ACC1 contains 2,346 amino acid residues with a molecular weight of 265 317 
kDa and the ACC2 contains 2,483 amino acid residues with a molecular weight of 280 kDa  318 
(48). The difference of about 140 amino acids in the N-terminus of ACC2, explains the 319 
difference in location and function when compared to ACC1  (48, 49). 320 
11 
 
The both ACCs isoforms are mainly regulated by AMPK, that inactivates the enzyme by 321 
phosphorylation, and the protein phosphatase 2A, that dephosphorylate the enzyme and 322 
activates it  (43, 49). Besides, the AMPK is activated by AMP and deactivated by ATP; when 323 
AMP levels are low, the AMPK is inactive and the ACC is active  (43). Other molecules that 324 
regulates ACC are citrate (activation), palmitoyl-CoA (inactivation) and CoA  (43, 46, 48, 325 
49). In the transcriptional level, ACC is regulated by some transcription factors as the 326 
carbohydrate response element-binding protein (ChREBP) and SREBP-1c (normally 327 
activated by glucose and insulin, respectively)  (50). During the catalytic reaction of ACC 328 
(Figure legends 329 
Figure 1), bicarbonate plays an important role as it is the CO2 source for the biotin 330 
carboxylation; this bicarbonate molecule is synthesized from CO2 and water by -carbonic 331 
anhydrases (CAs), thus, evidencing that CAs are also important regulators of ACC  (43). One 332 
of these CAs, the CA9/CA12 has been determined as overexpressed in many tumors and it is 333 
associated with cancer progression  (51). There are also other novel regulators of the ACC 334 
activity as BRCA1 and AKR1B10 that are overexpressed in human carcinomas and are 335 
associated with an increase in the FA synthesis  (43). 336 
The ACC1 isoform, in particular, is regulated by a series of transcription factors controlled 337 
by glucose, insulin, thyroid hormones and catabolic hormones (49, 52); these transcription 338 
factors are the SREBP-1  (53), the liver X receptor/retinoid X receptor complex  (54), and the 339 
PPARγ co-activator (PGC)  (55). Specifically, the SREBP-1 is a key regulator of ACC1 (also 340 
of other lipogenic enzymes) in the transcriptional level as it is an effector of MAPK and PI3K  341 
(48, 49). In the translational level, ACC1 is activated by the human epidermal growth factor 342 
receptor-2 (HER2) mediated by PI3K/Akt/mTOR signaling pathway, as observed in breast 343 
cancer  (56).  344 
Inhibitors and cytotoxic effects. The overexpression of ACC, mainly the ACC1 isoform, 345 
has an important role in cancer treatment because it contributes to the survival of cancer cells 346 
when therapies targeting the Warburg effect are applied  (57). The mechanism of action is not 347 
fully understood yet, but it is the response of cancer cells to the AMPK activation-induced 348 
inhibition of ACC  (58). Also, it has been observed that the exogenous uptake of palmitic 349 
acid completely saves cancer cells from death, thus affecting the treatments that target ACC 350 
and FAS (mentioned in next section). Despite the ACC1 overexpression has been observed in 351 
many tumors, both isoforms of ACC seems to contribute almost equally to the lipid synthesis 352 
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as a studies have shown  (59). Moreover, the pharmacological inhibition of ACC leads to 353 
cancer cell cycle arrest and/or apoptosis in several cell lines  (43). 354 
The ACC inhibitors have been reviewed in a previous study  (60), but it is worth to 355 
mention the most important ones (Figure 3). First, Soraphen A (9, Figure 3) is a natural 356 
product isolated from the soil bacterium Sorangium cellulosum, with a structure that contains 357 
a lactone formed by seventeen carbon atoms, where the C3 and C7 of the ring are connected 358 
as a hemiketal  (61). It was initially recognized as a potent antifungal drug, but, further 359 
studies showed that it is also a potent inhibitor of eukaryotic ACC, binding specifically to the 360 
BC domain  (62). However, it has no effect on the BC domain of prokaryotic ACC (bacterial)  361 
(63). By analyzing the co-crystal structure of Soraphen A and the BC domain of ACC 362 
(yeast), it was evidenced that the entire macrocyclic portion binds to the BC domain, the 363 
methoxy groups at C11 and C12 positions act as H-bond acceptors, and the hydroxyl groups 364 
at C3 and C5 positions act as H-bond donors. Moreover, it was established that the binding of 365 
Soraphen A to the BC domain, interferes with the oligomerization of the domain, inhibiting 366 
ACC  (62). Further studies, evidenced that Soraphen A inhibits DNL in human hepatoma 367 
(HepG2 cell line) and prostatic cancer (LnCaP cell line)  (64), and also anti-cancer activity 368 
has been observed in other cancer cells  (65–67). In particular, Soraphen A inhibits the FA 369 
synthesis, promoting the FA -oxidation and reducing the PLs level in prostate cancer cells 370 
(LnCaP and PC-3M cell lines), inhibiting their proliferation  (58). Additionally shows 371 
antiviral activity  (68). However, Soraphen A has not been clinically used due to its poor 372 
drug-like properties. 373 
Pfizer researchers developed a metabolically stable piperidinyl derived analog, the CP-374 
640186 (10, Figure 3)  (69). It is a nonselective, reversible, and ATP noncompetitive inhibitor 375 
of ACC1/2, and has been shown to inhibit the synthesis of FAs and TGs in HepG2 cells  (69) 376 
and shows cytotoxic properties in lung cancer line  (70) . The authors reported an IC50 of 53 377 
nM for rACC1 (rat) and 61 nM for rACC2  (69). By studying the co-crystal structure of CP-378 
640186 and the CT domain of ACC (yeast), it was elucidated that the anthracene flat ring, the 379 
carbonyl group next to it, and the piperidine rings interact with the CT domain to produce the 380 
inhibitory effect  (71). 381 
Other piperidinyl derived compound that interacts similarly with the CT domain, is 382 
compound 11 (Figure 3), with a higher activity against ACC1/2 than compound 10. The 383 
metabolically stable compound 11 developed by Taisho has an IC50 of 101 nM for rACC1, 23 384 
nM for rACC2 and 76 nM for hACC1/2 (human). The authors reported that compound 11 385 
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inhibited the FA synthesis with an IC50 of 0.34 μM and increased the fatty acid oxidation 386 
with an EC50 of 0.58 μM in HepG2 cells  (72). Moreover, they found that the two aryl rings 387 
at the 2,6-position of the pyridine ring have distinct activities, one provides close 388 
hydrophobic space and the other interacts with the acetyl-CoA binding site.  389 
The potential of piperidine derived compounds, inspired researchers to develop 390 
spiropiperidine derived ACC inhibitors by fusing piperidine rings with side chains or 391 
aromatic rings, giving rise to more rigid compounds with better binding activity to the CT 392 
domain  (69). A potent inhibitor of hACC1/2 was developed by researchers from Merck 393 
Sharp & Dohme Corp and the University of Texas Southwestern Medical Center, the 394 
compound MK-4074 (12, Figure 3) with an IC50 of approximately 3 nM  (73). Clinical studies 395 
in healthy young male subjects have shown that MK-4074 reduces DNL in 96%. However, 396 
the plasma TGs were significantly elevated compared to the placebo group  (73). In this way, 397 
inhibition of ACC can decrease the malonyl-CoA levels, interfering with the synthesis of 398 
polyunsaturated FA, but it also leads to the activation of SREBP-1c and glycerol-3-phosphate 399 
acyltransferase (GPAT1), which increase the secretion of very low-density lipoprotein 400 
(VLDL), and thus produces hypertriglyceridemia  (73). 401 
After a series of optimizations and previous studies, the researchers of Shionogi & Co. 402 
developed a benzothiazole derivative with high activity and selectivity for ACC2, the 403 
compound 13 (Figure 3). Their results showed that it has good drug-like properties and 404 
suggested that the linker between the side chain and the aromatic ring was critical for the 405 
safety and efficacy of these types of compounds  (74). 406 
By optimizing a 2-azetidinyl-1,3-benzoxazole derivative, Takeda researchers developed a 407 
novel and selective ACC1 inhibitor, compound 14 (Figure 3). They reported an IC50 of 0.58 408 
nM for hACC1 and an IC50 of more than 10 μM for hACC2, and also it has good drug-like 409 
properties  (75). After a series of analyses, they found that the cyclopropyl ether aryl side 410 
chain enhances the selectivity of ACC1, and several bicyclic cores improve the inhibitory 411 
activity  (75). Recently, Takeda researchers developed a series of 1,3 benzoxazole derivatives 412 
(with a similar structure to compound 14); one results to be a potent ACC1 inhibitor with 413 
good drug-like properties  (76). The compound 15 (Figure 3) inhibits both ACC isoforms, but 414 
is more potent against hACC1 (IC50 = 1.5 nM) than against hACC2 (IC50 = 140 nM). In vivo 415 
studies showed that compound 15 reduced the malonyl-CoA levels in HCT-116 xenograft 416 
tumors and also that inhibits tumor growth in a 786-O xenograft mouse model at doses of 417 
more than 30 mg/kg  (76). 418 
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In 2016, Nimbus therapeutics developed an efficient, reversible and specific ACC1/2 non-419 
selective inhibitor, the ND-630 (16, Figure 3)  (77). It inhibits ACC by interacting with its 420 
phosphopeptide-acceptor and dimerization site, interfering with dimerization  (77). In the 421 
same way as Soraphen A, ND-630 interacts within the dimerization site of the enzyme with 422 
the same residues as the AMPK-phosphorylated ACC peptide tail to disrupt subunit 423 
dimerization and inhibit ACC activity, but ND-630 is more potent because it fills a narrow, 424 
deep pocket in the BC domain  (77). Despite its potent ACC inhibitory effect, further studies 425 
showed that ND-630 has weak cytotoxicity against lung tumors  (78). In contrast, its primary 426 
amide, ND-646 (17, Figure 3), showed both properties, a potent ACC inhibition and FA 427 
synthesis  (79), and a strong cytotoxic effect against lung tumors  (78). By the same 428 
inhibition mechanism of ND-630, ND-646 binds the BC domain of ACC and generates its 429 
consecutive dephosphorylation, this prevents the action of AMPK and then ACC is not able 430 
to dimerize  (79). 431 
In 2019, Li et al. performed small structural changes in ND-646, leading to the discovery 432 
of several compounds with a better cytotoxic effect  (78). One is compound 18 (Figure 3), 433 
which acts by the same mechanism of ND-646 and has an IC50 of 6.87 nM for hACC1. In 434 
non-small-cell lung cancer (NSCLC), the ACC1 mRNA is overexpressed (like in many other 435 
types of cancer mentioned above). By using compound 18, the growth of A549 cells was 436 
inhibited (IC50 = 16.2 nM), leading apoptosis  (78).  437 
To sum up, the ACC inhibition is not only a target for cancer but also for other metabolic 438 
diseases like diabetes, obesity and fatty liver with positive results. Therefore, targeting ACC 439 
in the cancer therapy could implicate some non-desired side effects.  440 
 441 
FAS 442 
Function and description. The human fatty acid synthase (hFAS) is a complex 443 
homodimeric cytosolic enzyme of 552 kDa, that catalyzes the formation of palmitate (C16) 444 
from acetyl-CoA and malonyl-CoA in the presence of NADPH (Figure legends 445 
Figure 1)  (80). FAS has seven catalytic domains, which are (in linear order from the 446 
carboxyl terminus): thioesterase (TE), acyl-carrier protein (ACP), -ketoacyl reductase (KR), 447 
enoyl reductase (ER), -hydroxyacyl dehydratase (DH), malonyl/acetyl transferase (MAT) 448 
and -ketoacyl synthase (KS). Moreover, there are two additional nonenzymatic domains, the 449 
pseudoketoreductase (KR) and the peripheral pseudomethyltransferase (ME)  (81). 450 
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As mentioned above, FAS catalyzes the final step of the FA biosynthesis. Starting with a 451 
load of acetyl (from acetyl-CoA) onto the terminal thiol of the phosphopantetheine cofactor 452 
of the ACP, this process is performed by the MAT (82). The ACP passes the acetyl moiety 453 
over the active site cysteine of the KS. Subsequently, the MAT transfers the malonyl group of 454 
malonyl-CoA to the ACP, and the KS catalyzes the decarboxylative condensation of the 455 
acetyl and malonyl moieties to an ACP-bound -ketoacyl intermediate. Then, the -carbon 456 
position is modified by the NADPH-dependent KR, DH, and NADPH-dependent ER 457 
domains to finally generate a saturated acyl group product with two extra carbon units. This 458 
molecule is the starting substrate for the next reactions of elongation until a fatty acid of 16 to 459 
18 carbon atoms of length is obtained. Finally, the products are released from ACP as free 460 
FAs by the TE domain  (82). 461 
In cancer cells, the FAS overexpression is one of the most frequent phenotypic alterations, 462 
moreover, it is related to a higher risk of cancer recurrence and death  (83). FAS 463 
overexpression has been evidenced in many human cancer cell lines including breast, 464 
colorectum, prostate, bladder, ovary, esophagus, stomach, lung, oral tongue, oral cavity, head 465 
and neck, thyroid and endometrium, among others  (83, 84). Normally, FAS is mainly 466 
regulated by nutritional signals and is expressed in hormone-sensitive cells and cells with 467 
high lipid metabolism  (85). In contrast, FAS regulation in cancer cells implicates the activity 468 
of several transcriptional and post-translational factors (growth factors, hormones, and their 469 
receptors), in parallel with microenvironmental effects  (81). Two well-studied pathways 470 
involved in the FAS regulation, are the MAPK and the PI3K/Akt pathways  (86). The HER2 471 
and epidermal growth factor (EGF) receptors are involved in the downstream of PI3K/Akt 472 
and MAPK signaling pathways, which subsequently activates FAS expression 473 
transcriptionally  (87). Moreover, FAS expression can be amplified by the crosstalk between 474 
sex hormones, growth factors, and their receptors  (26). Both Akt and MAPK transduction 475 
pathways regulate FAS by the same mechanism. They regulate the expression of SREBP-1c 476 
which interacts with regulatory elements in the FAS promoter  (81). Also, SREBP-1c is 477 
directly regulated by the proto-oncogene FBI-1 (Pokemon) through its DNA-binding domain, 478 
and thus synergistically activates the FAS transcription  (88). Another transcription factor 479 
that is also regulated as SREBP-1c and is highly implicated in the FAS expression, is the 480 
ChREBP  (89). There are also other factors as NAC1, the acetyltransferase P300, and some 481 
microRNAs that regulate FAS expression in tumor cells  (90). 482 
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In breast cancer, FAS mediates the overexpression of S14, a lipogenesis-related nuclear 483 
protein that is regulated by SREBP-1c, supporting cell growth and survival  (91). Moreover, 484 
in SK-BR-3 and BT-474 breast cancer cell lines, FAS might be regulated by another 485 
mechanism, via mTOR-mediated translational induction  (56). By this mechanism, HER2 is 486 
overexpressed and with-it higher levels of FAS are observed  (81). In prostate cancer, the 487 
ubiquitin-specific protease 2a (USP2a) is overexpressed and plays a critical role in cell 488 
survival. It may interact with FAS to stabilize it through the removal of ubiquitin  (92). 489 
USP2a is regulated by androgen and its inactivation results in the FAS protein decrease and 490 
enhanced apoptosis  (81).  491 
Microenvironmental effects as hypoxia and acidity have important roles in the regulation 492 
of FAS  (81). It has been evidenced that under hypoxic conditions in human breast cancer cell 493 
lines, FAS is upregulated  (93). Moreover, Furuta et al. found that SREBP-1c is also 494 
upregulated as an effect of the phosphorylation of Akt with the subsequent activation of the 495 
hypoxia-inducible factor HIF1. Finally, excessive extracellular acid conditions could result in 496 
changes in the transcriptional activation of the FAS gene in breast cancer cells  (94). 497 
Inhibitors and cytotoxic effect. Since the discovery of FAS as an oncogenic target, many 498 
inhibitors have been developed and proved against several cancer cell lines. It has been 499 
evidenced that the FAS inhibition, stops the proliferation and induce the apoptosis of cancer 500 
cells, with minimal effects on normal cells  (90). Most of the FAS inhibitors have been 501 
previously reviewed  (81, 95, 96), but it is worth to mention the most important, promising 502 
and potent inhibitors that are found in the literature (Figure 4). First, the synthetic compound 503 
C75, a weak irreversible FAS inhibitor with an IC50 between 200 - 500 M (racemic mixture)  504 
(96–98). C75 interacts with FAS in different domains, specifically with the KS, TE, and ER 505 
domains  (99); showing anticancer activity in many cancer cell lines and xenografts models  506 
(100–102). However, in vivo studies showed that C75 has a negative side effect; it reduces 507 
food intake and induces body weight loss  (103, 104). Further studies showed that the (–)-508 
C75 enantiomer (19, Figure 4) is capable of inhibiting FAS in vitro, producing a cytotoxic 509 
effect in several cancer cell lines without affecting food consumption  (105). On the other 510 
hand, it was evidenced that the (+)-C75 enantiomer inhibit CPT1 and produce anorexic 511 
effects. With these results, Makowski et al. developed a series of C75-based inhibitors taking 512 
into account the enantiomeric selectivity of FAS  (98, 106). They found that the elongation of 513 
the aliphatic chain or the introduction of larger groups in the β-position of the lactone causes 514 
a decrease in the inhibitory activity of FAS (106). This reduced structure-activity relationship 515 
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study led to the development of a better FAS inhibitor, the (–)-UB006 (20, Figure 4) with an 516 
IC50 of 220 M for hFAS  (98). In vitro studies showed that (–)-UB006 is more cytotoxic 517 
than C75 (racemic mixture) against several cancer cells; but specifically, against the 518 
OVCAR3 cell line, it showed to be 40 times more cytotoxic than C75. Furthermore, in vivo 519 
administration of (–)-UB006, evidenced that it does not affect the food intake and body 520 
weight. There are other C75-based inhibitors with no apparent negative side effects as C93 521 
and C247  (107). 522 
Orlistat (21, Figure 4) is a potent FAS inhibitor that was initially designed for obesity 523 
treatment, moreover, it is an FDA-approved pancreatic lipase inhibitor  (95). Orlistat forms a 524 
covalent adduct with the serine of the TE domain and has an IC50 of 0.9 M  (96, 108). It has 525 
shown tumor growth inhibition in xenograft models of prostate cancer and melanoma, and 526 
also reduced proliferation and enhanced apoptosis in breast cancer that overexpresses HER2. 527 
However, Orlistat has poor oral bioavailability and metabolic stability, and thus it is difficult 528 
to use for cancer treatment  (95). Moreover, the use of a drug-delivery system based on 529 
nanoparticles for Orlistat can improve its bioavailability, water-solubility and even its 530 
cytotoxic effect on aggressive breast cancer models  (109, 110).  531 
In 2014, GlaxoSmithKline pharmaceutical company developed a highly potent, reversible 532 
and specific inhibitor of the KR domain of hFAS  (111). The compound GSK2194069 (22, 533 
Figure 4), has an IC50 of 7.7 nM for hFAS and showed acceptable solubility and permeability. 534 
The authors demonstrated that GSK2194069 decrease the DNL, producing a potent inhibition 535 
in the cancer cell growth and proliferation in gastric and non-small-cell lung cancer cell lines. 536 
Moreover, they identified that GSK2194069 interacts specifically with the KR domain and 537 
works as a competitive inhibitor. Further studies evidenced that treatment with GSK2194069 538 
in prostate cancer C42b cell xenografts inhibited the tumor growth with no apparent side 539 
effects  (112). 540 
Sagimet Biosciences (previously 3-V Biosciences) developed a new generation of highly 541 
potent, reversible, FAS inhibitors  (113). One of them is TVB-3166 (23, Figure 4), that has an 542 
IC50 of 0.042 M for FAS (from rabbit). It is capable of stopping the FA synthesis and 543 
disrupt the lipid raft structure, affecting all the membrane-associated molecules and signaling 544 
pathways as Ras, Akt-mTOR, and Wnt--catenin  (114). In vivo studies showed that a single 545 
daily dose can inhibit FAS for 10-12 h each day, inducing xenograft tumor growth inhibition 546 
in lung, ovarian and pancreatic tumor models  (114). These results showed that an 547 
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irreversible inhibitor is not necessary to stop the tumor growth in vivo. Moreover, TVB-3166 548 
does not have any apparent negative side effects. 549 
Another compound developed by Sagimet Biosciences, is the TVB-2640 (24, Figure 4), 550 
which is the first and only FAS inhibitor that has reached the clinical trials until date  (95). 551 
TVB-2640 is described as a highly potent, selective and reversible FAS inhibitor that acts in 552 
the KR domain and has an IC50 of 0.05 M  (115). In 2017, the phase 1 clinical trial of TVB-553 
2640 in patients with solid tumors was finished, demonstrating its antitumor activity in 554 
monotherapy and co-treatment with paclitaxel  (116). Some common negative side effects 555 
were observed including alopecia, palmar-plantar erythrodysesthesia, decreased appetite, 556 
among others. Nowadays, the phase 2 of clinical trials of TVB-2640 (monotherapy and/or co-557 
treatment) is underway, including the treatment of lung, colon, breast, and astrocytoma 558 
cancer (NCT03808558, NCT02980029, NCT03179904, and NCT03032484). Moreover, 559 
partial results of the phase 2 trial of TVB-2640 in combination with Bevacizumab in patients 560 
with the first relapse of high-grade astrocytoma, showed that the co-treatment is well 561 
tolerated in humans  (117). 562 
In 2016, Alwarawrah et al. discover a potent thiophenopyrimidine-based FAS inhibitor 563 
with broad antitumor activity against various non-tumorigenic and aggressive tumor-forming 564 
breast cancer cell lines  (118). Fasnall (25, Figure 4) with an IC50 of 3.71 M for hFAS, can 565 
produce a significant change in the global cellular lipid profile. Its mechanism of action 566 
includes the increase of intracellular levels of ceramide (also in DAGs and unsaturated FA) 567 
which increases the apoptosis of cancer cells. Moreover, Fasnall inhibits the formation of PLs 568 
with saturated acyl chains and promotes the uptake of unsaturated FAs, affecting critically 569 
the lipid raft structure and functioning  (119). Fasnall treatment has no apparent negative side 570 
effects and its combination with other chemotherapeutic agents as carboplatin augments the 571 
tumor volumes reduction and survival in vivo studies  (118). All these characteristics and the 572 
ease of adaptability of the Fasnall synthetic route, suggest that it can be further optimized to 573 
developed new derivatives with better pharmacological properties. 574 
In 2018, Lu et al. developed a series of spirocyclic imidazolinone FAS inhibitors; one of 575 
them showed high FAS inhibitory activity with good cellular activity and oral bioavailability  576 
(120). The compound JNJ-54302833 (26, Figure 4) has an IC50 of 28 nM for hFAS and 577 
effectively inhibits the proliferation of several cancer cell lines including ovarian, prostate, 578 
lymphoma, leukemia, lung and breast. The authors found that one compound of the series of 579 
spirocyclic imidazolinone FAS inhibitors (not exactly JNJ-54302833) binds to the KR 580 
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domain by H-bonds and also hydrophobic interactions occurred with the KR and non-581 
catalytic domains of FAS  (120). In 2019, Infinity Pharmaceuticals published the discovery of 582 
a potent and irreversible inhibitor of hFAS, the IPI-9119 (27, Figure 4)  (121). It has an IC50 of 583 
0.3 nM for hFAS and inhibits the TE domain by promoting acylation of the catalytic serine. 584 
Authors evidenced that IPI-9119 significantly reduced prostate cancer cell growth, and 585 
induced cell cycle arrest and apoptosis in PCa cells. Moreover, FAS inhibition generated an 586 
entire lipid homeostasis change, including the accumulation of polyunsaturated FAs produced 587 
by the uptake and use of exogenous FAs. Also, the cholesterol synthesis was increased as a 588 
type of redirection of the unused acetyl-CoA. Therefore, it is evidenced that PCa cells tried to 589 
compensate for the DNL deficiency by up-regulating genes encoding enzymes and 590 
transcription factors involved in lipid synthesis  (121). Further investigations are necessary to 591 
understand these anomalies caused by IPI-9119 treatment. 592 
FORMA Therapeutics developed a series of novel piperazine derivative FAS inhibitors; 593 
one of them is the compound FT113 (28, Figure 4) with an IC50 of 0.213 M for hFAS  (122). 594 
The authors reported that several H-bond interactions occurred between the hydroxyl and 595 
carbonyl of the hydroxy-cyclopropyl amide and the active site residues of the KR domain. 596 
These observations were determined by the X-ray co-crystal structure of FT113 bound to a 597 
ΨME-ΨKR-KR tridomain FAS construct  (122). FT113 was the compound with the best 598 
balance between physicochemical and pharmacokinetic properties and potency. Moreover, 599 
FT113 showed anti-proliferative activity against prostate (PC3 cell line), breast (BT-474 cell 600 
line) and leukemia (MV-411 cell line) cancer cells. After 16 days of treatment with FT113, it 601 
was evidenced an increase in malonyl-CoA levels in the tumors as well as a tumor growth 602 
inhibition of 32% and 50%, by treatment with 25 and 50 mg/kg respectively, compared to the 603 
vehicle. 604 
It has been evidenced that FAS is a viable target for the inhibition of FA biosynthesis, as 605 
many compounds showed high FAS inhibitory activity and cytotoxic effect against several 606 
cell lines, with no apparent side effects. Moreover, there is one compound (TVB-2640) that is 607 
currently been tested in humans, suggesting that FAS targeting has a great potential for 608 
anticancer therapy. It is important to mention that nowadays, we have new tools for the 609 
discovery of FAS inhibitors, like the computational screening  (123). With new tools of this 610 
kind, there is more ease of discovery, and optimization of new compounds with lower 611 
expenses and time in the process. 612 
 613 
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MAGL 614 
Function and description. In DNL, the MAGL liberates the stored fatty acids for 615 
metabolic and signaling purposes, supporting and promoting the migration, invasion, 616 
survival, and growth of tumors in aggressive human cancers  (124). This enzyme has been 617 
found in elevated levels, together with free fatty acids (FFAs), in several aggressive human 618 
cancer cell lines  (124). The MAGL controls the FFAs level in cancer cells through the 619 
hydrolysis of monoacylglycerols (MAGs) (Figure legends 620 
Figure 1)  (124). In normal cells, the MAGL controls the levels of MAGs and not the 621 
FFAs level, evidencing that in cancer cells this pathway is altered (as others already 622 
mentioned) to satisfy the pathogenic requirements  (124, 125). The mechanism of MAGL-623 
stimulation for the cancer aggressiveness is through the action of FFA-derived products  624 
(124). Some secondary lipid metabolites such as LPL (including lysophosphatidylcholine 625 
(LPC), LPA, lysophosphatidylethanolamine (LPE), PA), Prostaglandin E2 (PGE2), and ether 626 
lipids (Monoalkylglycerol (MAGE), alkyl LPE) are regulated by MAGL; all of them support 627 
cancer malignancy but LPA and PGE2 in greater extent  (124, 126). Moreover, MAGL is the 628 
primary enzyme that degrades endogenous cannabinoid 2-arachidonoylglycerol (2-AG) in 629 
vivo  (127), moreover, 2-AG is the principal signaling molecule of MAGs and activates the 630 
CB1 and CB2 receptors  (124, 128). In particular, the CB1 receptor has been highly 631 
implicated in the aggressiveness of prostate cancer  (127, 129). Therefore, it can be said that 632 
MAGL controls the FA and endocannabinoid pathways that support the aggressiveness in 633 
prostate cancer  (127). Besides, it has been observed that the CB2 receptor activation 634 
promotes colon cancer and recently, it was evidenced that the attenuation of CB2 signaling 635 
suppress the tumor growth  (130). Also, these endocannabinoid (CB1 and CB2) receptors 636 
have other functions related to pain, inflammation, neurodegeneration, and anxiety  (131). 637 
MAGL is part of the / hydrolase superfamily of enzymes  (132). It is found as a dimer 638 
of 33 kDa with 313 residues, it has two protein molecules per asymmetric unit with the 639 
catalytic site facing the PL membrane (133). MAGL is located in the cytosol and cell 640 
membranes (amphipathic behavior), so it is soluble in the cytosol and at the same time, it can 641 
interact with the PL membrane to recruit its substrate  (134). Moreover, it has been observed 642 
that MAGL exist in two distinct conformations, closed and open, these correspond to 643 
inaccessible or solvent-exposed active site  (134). This special characteristic evidenced that 644 
MAGL regulates the entering of 2-AG to the catalytic site through the CPe flexible control of 645 
the lid domain opening  (134). It was hypothesized that the hydrophobic character of the lid 646 
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domain serves to located the MAGL close to the PL membrane, facilitating the 2-AG 647 
recruitment  (134). When the substrate enters the active site, the MAGL takes its closed-form 648 
and dissociates from the membrane in parallel to the cleaving the 2-AG, then the MAGL 649 
takes again the open conformation and re-associates to the membrane  (134). The mechanism 650 
of action of the MAGL has not been fully elucidated yet, but as mentioned before, an 651 
important part of it is now understood and might lead to the development of better inhibitors 652 
for this enzyme. 653 
About the regulation of MAGL, very little is known of the post-transcriptional and post-654 
translational modifications; there is no evidence of phosphorylation or other modifications to 655 
date  (135). There is evidence pointing out that there are slight variations between the MAGL 656 
enzymes from adipose tissues, liver, heart, lung, stomach, kidney, spleen, kidney and adrenal 657 
gland, with the ones from brain, testis and skeletal muscle (135, 136). Therefore, there is the 658 
possibility that the post-transcriptional and/or post-translational modifications could occur 659 
depending on the particular need of the cell in a distinct tissue or physiological state  (135). 660 
In general terms, the regulation of MAGL is unknown, therefore, more studies are required to 661 
understand it (especially the human MAGL) and thus design better and more selective 662 
inhibitors. 663 
Inhibition and cytotoxic effect. It has been evidenced that by inhibiting the MAGL, the 664 
tumorigenesis and cancer progression are suppressed in several cancer cell lines  (39, 137), 665 
but also its inhibition can have other implications in neurodegeneration, inflammation and 666 
metabolic disorders  (138). Moreover, there are other serine hydrolases such as fatty acid 667 
amide hydrolase (FAAH), α/β hydrolase domain 6 (ABHD6), and α/β hydrolase domain 12 668 
(ABHD12) that have similar binding site properties (to MAGL); although they exert different 669 
functions and have different endogenous substrates in human  (138). Therefore, the analysis 670 
of the selectivity profile of MAGL inhibitors is very important for the development of new 671 
and better compounds.  672 
Some MAGL inhibitors have been reviewed previously  (138, 139), but it is important to 673 
mention the most promising and new ones (Figure 5). In 2008, Muccioli et al. developed a 674 
good inhibitor of MAGL, the CAY10499 (29, Figure 5)  (140). The carbamate derivative 675 
CAY10499, is a covalent irreversible inhibitor of MAGL, with an IC50 of 134 nM for 676 
hMAGL  (141). Although, CAY10499 is not a selective inhibitor of MAGL, as it is also 677 
active against FAAH  (140). The authors suggested that the active moiety of CAY10499 is 678 
the 5-methoxy-1,3,4-oxadiazol-2(3H)-one moiety and not the carbamate. Further studies, 679 
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showed that CAY10499 is active against five tumor cell lines, human breast (MDA-MB-680 
231), colorectal (HCT116), and ovarian (OVSAHO, CAOV3, COV318, OVCAR3, and 681 
SKOV3) cancer cell lines  (141, 142).  682 
The first selective and in vivo active, irreversible inhibitor of MAGL was synthesized in 683 
2009 by Long et al.  (143). The JZL184 (30, Figure 5) is a piperidine carbamate compound, 684 
that binds covalently and irreversibly by carbamylating a serine residue in the active site of 685 
MAGL; it has an IC50 of 6 nM for hMAGL. In vivo studies showed several beneficial effects 686 
by its administration, including analgesic, antinociceptive, anti-inflammatory, 687 
gastroprotective, antidepressant and anxiolytic effects  (144, 145). Moreover, JZL184 has 688 
shown anticancer effects against colorectal cancer  (146) and hepatocellular carcinoma 689 
(HCC)  (137). In colorectal cell lines, it reduced the tumor cell progression and increased 690 
apoptosis (correlated with MAGL inhibition)  (146). In HCC cell lines, it significantly 691 
increased apoptosis and reduced tumor growth, and it even decreases the invasion ability 692 
HCC cell line SMMC-772  (137). Moreover, in C8161 and SKOV3 aggressive cancer cells, 693 
the tumor growth and migration rate were reduced by the administration of JZL184 once per 694 
day (40 mg/kg)  (124). Nomura et al. evidenced that JZL184 blocks the conversion of LPA 695 
and PGE2 from MAGs in aggressive cancer cells, which correlates with the tumor growth 696 
and migration reductions. Further investigations  (147), generate a more selective JZL184 697 
derivative with O-hexafluoroisopropyl as a leaving group, the KML29 (31, Figure 5). This 698 
compound has an IC50 value of 5.9 nM for hMAGL and has shown a complete selectivity for 699 
MAGL over FAAH  (148). KML29, as other carbamate derivatives, binds covalently and 700 
irreversibly to MAGL by the formation of a carbamylated enzyme-inhibitor adduct  (147). 701 
Although, there is not any study of the anticancer activity of this compound until the date.  702 
After a series of optimizations of carbamate derivatives, the Pfizer's research group 703 
developed the irreversible inhibitor PF-06795071 (32, Figure 5) with an IC50 of 3nM for 704 
hMAGL  (149). This compound has great drug-like properties thanks to its novel stereo-705 
defined trifluoromethyl glycol leaving group. PF-06795071 was studied against 706 
neuroinflammatory disease and showed high in vivo efficacy  (149), but there are no studies 707 
about its use against cancer. In 2013, a series of urea-based MAGL inhibitors were developed 708 
by Aaltonen et al.; the most potent of them was JJKK-048 (33, Figure 5) with an IC50 value of 709 
0.36 nM against hMAGL  (150). This compound irreversible inhibitor was proved to be 710 
selective for MAGL against other serine hydrolases as FAAH and ABHD6. The proposed 711 
mechanism of action is very similar to the carbamates derived inhibitors, JJKK-048 also 712 
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forms a carbamate adduct with a serine in the active site of MAGL and the triazole (1,2,4-713 
triazolate anion) acts as the leaving group. In vivo studies of JJKK-048 in C8161 melanoma 714 
cells, shows that it is highly selective for MAGL but further information about its impact on 715 
cell proliferation, migration, and invasiveness has not been reported  (150). 716 
The irreversible inhibition of MAGL has many negative effects in vivo, as the loss of the 717 
analgesic effects and cross-tolerance to CB1 agonists  (151). Also, it generates physical 718 
dependence, damages the endocannabinoid-dependent synaptic plasticity and desensitizes 719 
brain CB1 receptors. The chronic inhibition of MAGL has many obstacles to be an anticancer 720 
treatment, therefore, the development of reversible inhibitors is of great importance. In 2018, 721 
a selective and reversible inhibitor of MAGL has been developed by Takeda Pharmaceutical, 722 
the compound 34 (Figure 5)  (152). This compound with piperazinyl pyrrolidin-2-one 723 
structure, showed great balance between metabolic stability (29 L/min/mg) and inhibition 724 
activity (IC50 = 3.6 nM). The authors reported that it was selective against MAGL over 725 
FAAH, but selectivity over other serine hydrolases has not been reported yet. The 34 726 
produced a dramatic reduction of arachidonic acid (25%) and an increase of 2-AG (340%) in 727 
mice brain in vivo. This compound was designed for the treatment of neurodegenerative 728 
diseases and no anti-cancer studies have been developed yet. 729 
In 2018, Aghazadeh et al. developed a pyrazole-3-carboxamide derivative after a series of 730 
optimization  (142). The compound 35 (Figure 5), a pyrazole-3-carboxamide derivative that 731 
acts as an efficient reversible inhibitor of MAGL, with an IC50 of 0.51 M against hMAGL. 732 
In vitro studies showed that compound 35 has promising antiproliferative activity against two 733 
ovarian cancer cell lines (OVCAR-3 and CAOV-3). Moreover, compound 35 has selectivity 734 
for MAGL over FAAH, ABHD6, and ABHD12; also, it did not show significant binding to 735 
any of the CB1 and CB2 cannabinoid receptors. Recently, Granchi et al. developed a 736 
benzoylpiperidine-based potent and reversible inhibitor of MAGL, the compound 36 (Figure 737 
5)  (141). Compound 36 has a value of 80 nM for hMAGL and showed high selectivity over 738 
FAAH, ABDH6, ABDH12, CB1 and CB2 (IC50 > 10 μM in all cases). Also, in vitro studies 739 
showed antiproliferative activities in human breast MDA-MB-231, colorectal HCT116, and 740 
ovarian CAOV3, OVCAR3, and SKOV3 cancer cells at micromolar concentrations. In vivo 741 
studies proved that compound 36 inhibits MAGL, as it significantly increased the 2-AG 742 
levels in brain and plasma after intraperitoneal injection into C57BL6 mice. 743 
Targeting MAGL for the cancer treatment could result in the disruption of cancer cells 744 
proliferation but also could lead to neurodegeneration, inflammation and metabolic disorders. 745 
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The development of future MAGL inhibitors must focus on the selectivity and reversibility of 746 
the inhibition to avoid possible side effects.747 
748 
749 
Conclusions 750 
Lipid metabolism is a key player in cancer cell survival. Those enzymes that regulate the 751 
synthesis of FAs are often overexpressed in many cancer cell lines and their inhibition can 752 
result in the disruption of cancer cell proliferation. In this review, inhibitors of the three 753 
enzymes involved in the anabolism of FFAs from citrate (ACLY, ACC and FAS) and one 754 
involved in the catabolism of FFAs from MAG (MAGL) have been analyzed as potential 755 
antitumor drugs. Among them, inhibitors of FAS are very promising, since they showed 756 
cytotoxicity against several cancer cell lines and one of them (TVB-2640) is currently 757 
evaluated in clinical trials. Inhibitors that target ACC and MAGL should focus on selectivity 758 
to avoid possible side effects, because the inhibition of these enzymes affects other metabolic 759 
diseases. On the other hand, inhibitors addressed to ACLY need to be studied more 760 
exhaustively to assess their effectiveness for cancer.   761 
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Figure legends 776 
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Figure 1. Overview of lipogenesis in cancer and four target enzymes responsible for fatty 777 
acid synthesis. Cancer cells obtain free fatty acids (FFA) primarily from de novo 778 
biosynthesis. Glucose is converted to pyruvate, via aerobic glycolysis. Pyruvate is 779 
metabolized to citrate within the mitochondria in the Krebs cycle to produce ATP. The citrate 780 
excess is expelled to the cytosol where it enters to the lipogenic pathway. ATP-citrate lyase 781 
(ACLY) catalyzes the production of acetyl-CoA, which is then carboxylated to malonyl-CoA 782 
by Acetyl-CoA carboxylase (ACC). The FAS then catalyzes palmitate biosynthesis from 783 
acetyl-CoA and malonyl-CoA. On the other hand, lipid stores can be used to obtain FFA due 784 
to a high activity of Monoacylglycerol lipase (MAGL). Cancer cells with a high proliferation 785 
rate need free fatty acids for phosolipids formation of the new membranes, for signaling 786 
molecules as ceramides or sphingolipids or to obtain energy via β-oxidation. All the indicated 787 
enzymes have been studied as potential therapeutic targets against cancer. 788 
 789 
Figure 2. Structure and half-maximal inhibitory concentration (IC50) of selected ACLY 790 
inhibitors. The organism from which ACLY was extracted and the cell line of the 791 
cytotoxicity studies are indicated in parenthesis. 792 
 793 
Figure 3. Structure and half-maximal inhibitory concentration (IC50) of selected ACC 794 
inhibitors. The organism from which ACC was extracted, the isoform, and the cell line of the 795 
cytotoxicity studies are indicated in parenthesis. 796 
	797 
Figure 4. Structure and half-maximal inhibitory concentration (IC50) of selected FAS 798 
inhibitors. The organism from which FAS was extracted and the cell line of the cytotoxicity 799 
studies are indicated in parenthesis. 800  801 
Figure 5. Structure and half-maximal inhibitory concentration (IC50) of selected hMAGL 802 
inhibitors. The cell line of the cytotoxicity studies is indicated in parenthesis in each case 803 
 804 
Figure 6. The inhibitors reviewed in this work. Inhibition of lipogenic enzyme produce 805 
cancer cells death due fatty acid starvation which are the building blocks for membranes, pro-806 
survival signaling molecules and source of energy in hypoxic environment as is a solid 807 
tumor.  808 
 809 
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Table 1. Summary of selected lipogenic enzyme inhibitors, their targets and relevance in 810 
cancer therapy   811 
 812 
813 
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